IMMIX BIOPHARMA INC (IMMX) Stock News

NASDAQ:IMMX - US45258H1068 - Common Stock

2.22 USD

-0.07 (-3.06%)

Last: 8/29/2025, 8:00:02 PM

2.28 USD

+0.06 (+2.7%)

After Hours: 8/29/2025, 8:00:02 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

IMMX Latest News, Press Relases and Analysis

All

Press Releases

5 days ago - By: Immix Biopharma, Inc.

Immix Biopharma to Present at the Stifel 2025 Healthcare Conference

5 days ago - By: Immix Biopharma, Inc.

Immix Biopharma to Present at the Stifel 2025 Healthcare Conference

24 days ago - By: Immix Biopharma, Inc.

Immix Biopharma Announces Other Serious Diseases Strategy

24 days ago - By: Immix Biopharma, Inc.

Immix Biopharma Announces Other Serious Diseases Strategy

2 months ago - By: Immix Biopharma, Inc.

Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion

2 months ago - By: Immix Biopharma, Inc.

Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion

2 months ago - By: Immix Biopharma, Inc.

Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis

2 months ago - By: Immix Biopharma, Inc.

Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis

3 months ago - By: Zacks Investment Research

Immix Biopharma (IMMX) Upgraded to Buy: What Does It Mean for the Stock?

3 months ago - By: Immix Biopharma, Inc.

Immix Biopharma Attends FDA CEO Forum in Washington DC

3 months ago - By: Immix Biopharma, Inc.

Immix Biopharma Attends FDA CEO Forum in Washington DC

3 months ago - By: Yahoo Finance - Mentions: RMBS ONC SERV UBER ...

H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial

3 months ago - By: Immix Biopharma, Inc.

Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

3 months ago - By: Immix Biopharma, Inc.

Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

3 months ago - By: Benzinga - Mentions: EVO RAPT ONCO ALTS ...

12 Health Care Stocks Moving In Friday's Intraday Session

3 months ago - By: Immix Biopharma, Inc.

Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2

3 months ago - By: Immix Biopharma, Inc.

Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2

3 months ago - By: Benzinga - Mentions: EVO OTLK BWAY PDSB ...

12 Health Care Stocks Moving In Friday's Pre-Market Session

3 months ago - By: Immix Biopharma, Inc.

Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

3 months ago - By: Immix Biopharma, Inc.

Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

3 months ago - By: Immix Biopharma, Inc.

Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis

3 months ago - By: Immix Biopharma, Inc.

Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis

4 months ago - By: Immix Biopharma, Inc.

Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025

4 months ago - By: Immix Biopharma, Inc.

Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025

7 months ago - By: Immix Biopharma, Inc.

Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis

7 months ago - By: Immix Biopharma, Inc.

Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis

8 months ago - By: Immix Biopharma, Inc.

Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T

8 months ago - By: Immix Biopharma, Inc.

Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T

8 months ago - By: Immix Biopharma, Inc.

Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis

8 months ago - By: Immix Biopharma, Inc.

Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis

9 months ago - By: Immix Biopharma, Inc.

Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis

9 months ago - By: Immix Biopharma, Inc.

Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis

9 months ago - By: Immix Biopharma, Inc.

Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024